Intra-arterial chemoradiation for T3-4 oral cavity cancer: treatment outcomes in comparison to oropharyngeal and hypopharyngeal carcinoma

Ilana Doweck, K Thomas Robbins, Sandeep Samant, Francisco Vieira, Ilana Doweck, K Thomas Robbins, Sandeep Samant, Francisco Vieira

Abstract

Background: Surgery followed by radiotherapy is the standard of care for resectable locally advanced oral cavity squamous cell carcinoma (SCC). We report the treatment outcomes of patients with T3-T4 SCC of the oral cavity treated with chemoradiation, an alternative approach.

Patients and methods: From a series of 240 patients with stage III-IV carcinoma of the upper aerodigestive tract who were treated consecutively according to the RADPLAT protocol, a subset analysis of 155 patients with T3-T4 SCC (Oral cavity SCC N = 22, oropharynx SCC N = 94 and hypopharynx SCC N = 39), was performed. The goal was to test the hypothesis that oral cavity SCC treated with chemoradiation has similar outcomes to the two comparison sites.

Results: With a median follow-up of 58 months, local disease control was 69% and the overall survival was 37%. In comparison, local disease control for the oropharynx and hypopharynx groups was 86% and 79% respectively. The overall survival rate for the oropharyngeal and hypopharyngeal groups were 41% and 6% respectively

Conclusion: Patients with locally advanced oral cavity cancer treated with the chemoradiation protocol RADPLAT have outcomes that are equal or better compared to patients with similar disease involving the oropharynx and hypopharynx.

Figures

Figure 1
Figure 1
Local-control rate stratified by site of disease.
Figure 2
Figure 2
Overall survival stratified by site of disease.

References

    1. Bourhis J, Amand C, Pignon JP, MACH-NC Collaborative Group Update of MACH-NC (meta-analysis of chemotherapy in head & neck cancer) database focused on concomitant chemotherapy [abstract 5505] Proc ASCO. 2004;22:489.
    1. Adelstein DJ, Li Y, Adams GL, Wagner H, Jr, Kish JA, Ensley JF, Schuller DE, Forastiere AA. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003;21:92–98. doi: 10.1200/JCO.2003.01.008.
    1. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, Peters G, Lee DJ, Leaf A, Ensley J, Cooper J. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 349:2091–2098. doi: 10.1056/NEJMoa031317. 2003 Nov 27.
    1. Robbins KT, Kumar P, Wong FSH, Hartsell WF, Flick P, Palmer R, Weir AB, 3rd, Neill HB, Murry T, Ferguson R, Hanchett C, Vieira F, Bush A, Howell SB. Targeted chemoradiation for advanced head and neck cancer: analysis of 213 patients. Head Neck. 2000;22:687–693. doi: 10.1002/1097-0347(200010)22:7<687::AID-HED8>;2-W.
    1. Doweck I, Robbins KT, Vieira F. Analysis of risk factors predictive of distant failure after targeted chemoradiation for advanced head and neck cancer. Arch Otolaryngol Head Neck Surg. 2001;127:1315–1318.
    1. Robbins KT, Doweck I, Samant S, Vieira F, Kumar P. Factors predictive of local disease control after intra-arterial concomitant chemoradiation (RADPLAT) Laryngoscope. 2004;114:411–417. doi: 10.1097/00005537-200403000-00004.
    1. Fein DA, Mendenhall WM, Parsons JT, McCarty PJ, Stringer SP, Million RR, Cassisi NJ. Carcinoma of the oral tongue: a comparison of results and complications of treatment with radiotherapy and/or surgery. Head Neck. 1994;16:358–365. doi: 10.1002/hed.2880160410.
    1. Palme CE, Gullane PJ, Gilbert RW. Current treatment options in squamous cell carcinoma of the oral cavity. Surg Oncol Clin N Am. 2004;13:47–70. doi: 10.1016/S1055-3207(03)00123-6.
    1. Koch WM, Lee DJ, Eisele DW, Miller D, Poole M, Cummings CW, Forastiere A. Chemoradiotherapy for organ preservation in oral and pharyngeal carcinoma. Arch Otolaryngol Head Neck Surg. 1995;121:974–980.
    1. Taylor SG, 4th, Murthy AK, Griem KL, Recine DC, Kiel K, Blendowski C, Hurst PB, Showel JT, Hutchinson JC, Jr, Campanella RS, Chen S, Caldarelli DD. Concomitant cisplatin/5-FU infusion and radiotherapy in advanced head and neck cancer: 8-year analysis of results. Head Neck. 1997;19:684–691. doi: 10.1002/(SICI)1097-0347(199712)19:8<684::AID-HED6>;2-1.
    1. Chougule P, Wanebo H, Akerley W, McRae R, Nigri P, Leone L, Safran H, Ready N, Koness RJ, Radie-Keane K, Cole B. Concurrent paclitaxel, carboplatin, and radiotherapy in advanced head and neck cancers: a phase II study – preliminary results. Semin Oncol. 1997;24:S19–57. S19–61.
    1. Lavertu P, Adelstein DJ, Saxton JP, Secic M, Eliachar I, Strome M, Larto MA, Wood BG. Aggressive concurrent chemoradiotherapy for squamous cell head and neck cancer: an 8-year single-institution experience. Arch Otolaryngol Head Neck Surg. 1999;125:142–148.
    1. Pradier O, Eberlein K, Weiss E, Jackel MC, Hess CF. Radiotherapy combined with simultaneous chemotherapy with mitomycin-C and 5-fluorouracil for inoperable head and neck cancer. Br J Radiol. 2001;74:368–374.
    1. Fornari G, Artusio E, Mairone L, Airoldi M, Bongioannini G, Amasio E, Rosmino C, Gabriele P. Paclitaxel and carboplatin in neo-adjuvant and concomitant chemoradiotherapy in locally advanced head and neck squamous cell carcinoma. Tumori. 2002;88:489–494.
    1. Airoldi M, Cattel L, Cortesina G, Giordano C, Pedani F, Recalenda V, Danova M, Gabriele AM, Tagini V, Porta C, Bumma C. Docetaxel, carboplatin and concomitant radiotherapy for unresectable squamous cell carcinoma of the head and neck: pharmacokinetic and clinical data of a phase I-II study. Am J Clin Oncol. 2004;27:155–163. doi: 10.1097/01.coc.0000054533.02062.09.
    1. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, Morrow M, (Eds.) AJCC Cancer Staging Manual. 6. Springer-Verlag, New-York; 2002.
    1. Mohr C, Bohndorf W, Carstens J, Härle F, Hausamen JE, Hirche H, Kimmig H, Kutzner J, Mühling J, Reuther J, et al. Preoperative radiochemotherapy and radical surgery in comparison with radical surgery alone: A prospective, multicentric, randomized DOSAK study of advanced squamous cell carcinoma of the oral cavity and the oropharynx (a 3-year follow-up) Int J Oral Maxillofac Surg. 1994;23:140–148. doi: 10.1016/S0901-5027(05)80288-7.
    1. Eckardt A, Rades D, Rudat V, Hofele C, Dammer R, Dietl B, Wildfang I, Karstens JH. Prospective phase II study of neoadjuvant radiochemotherapy in advanced operable carcinoma of the mouth cavity. 3-year outcome. Mund Kiefer Gesichtschir. 2002;6:117–121. doi: 10.1007/s10006-002-0370-y.
    1. Balm AJ, Rasch CR, Schornagel JH, Hilgers FJ, Keus RB, Schultze-Kool L, Ackerstaff AH, Busschers W, Tan IB. High-dose superselective intra-arterial cisplatin and concomitant radiation (RADPLAT) for advanced head and neck cancer. Head Neck. 2004;26:485–493. doi: 10.1002/hed.20006.
    1. Newman LA, Vieira F, Schwiezer V, Samant S, Murry T, Woodson G, Kumar P, Robbins KT. Eating and weight changes following chemoradiation therapy for advanced head and neck cancer. Arch Otolaryngol Head Neck Surg. 1998;124:589–592.
    1. Newman LA, Robbins KT, Logemann JA, Rademaker AW, Lazarus CL, Hamner A, Tusant S, Huang CF. Swallowing and speech ability after treatment for head and neck cancer with targeted intraarterial versus intravenous chemoradiation. Head Neck. 2002;24:68–77. doi: 10.1002/hed.10000.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe